Dynamic Technology Lab Private LTD 89bio, Inc. Transaction History

Dynamic Technology Lab Private LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.36 - $9.66 $291,102 - $382,072	-39,552 Reduced 65.22%	21,096 $156,000
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $348,299 - $519,352	47,647 Added 366.49%	60,648 $486,000
Q1 2024 May 14, 2024	SELL	$8.13 - $13.77 $207,672 - $351,740	-25,544 Reduced 66.27%	13,001 $151,000
Q4 2023 Feb 09, 2024	BUY	$6.66 - $16.03 $131,401 - $316,271	19,730 Added 104.86%	38,545 $431,000
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $128,235 - $165,276	8,515 Added 82.67%	18,815 $291,000
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $145,745 - $226,909	10,300 New	10,300 $195,000
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $64,490 - $148,724	11,683 Added 109.4%	22,362 $285,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $32,250 - $74,753	10,679 New	10,679 $62,000

173

125M

78.7K

979K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $391M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.